Does tirzepatide cause acid reflux? It can. In Zepbound's weight-management trials, about 4 to 5 in 100 adults reported reflux disease, compared with 2 in 100 on placebo. Indigestion was more common: about 9 to 10 in 100 versus 4 in 100.
That burning feeling is a recognized side effect, but every new chest or throat symptom isn't automatically reflux. Persistent symptoms belong in the conversation with the prescriber. Trouble swallowing, bleeding, or chest pain needs more immediate attention.
Does tirzepatide cause acid reflux? The label numbers
Two terms help make sense of the labels. GERD, short for gastroesophageal reflux disease, means repeated or troublesome backflow of stomach contents into the food pipe. Dyspepsia means indigestion: upper-belly burning, discomfort, or fullness. They overlap, but indigestion doesn't always mean acid is coming up.
As of October 1, 2026, the day this article was written, both current FDA-published labels carry “Revised: 08/2026.” These are the adult reflux and indigestion percentages in section 6.1 of the Zepbound label and Mounjaro label.
| Brand and symptom | Placebo | Tirzepatide 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Zepbound: GERD | 2% | 4% | 4% | 5% |
| Zepbound: indigestion | 4% | 9% | 9% | 10% |
| Mounjaro: GERD | 0.4% | 1.7% | 2.5% | 1.7% |
| Mounjaro: indigestion | 3% | 8% | 8% | 5% |
Zepbound's figures pool SURMOUNT-1 and SURMOUNT-2, weight-management trials in adults with or without type 2 diabetes. Mounjaro's figures pool SURPASS-1 and SURPASS-5 in adults with type 2 diabetes.
The lower Mounjaro percentages don't establish that one brand is gentler. These were different trial groups, treatments, and follow-up periods. Both brands contain tirzepatide. Mounjaro's GERD figures appear in the text below its main table, rather than in a separate table row.
Why tirzepatide heartburn can happen
Tirzepatide delays gastric emptying, meaning food leaves the stomach more slowly. Both labels say this effect is largest after the first dose and diminishes over time.
A stomach that stays fuller longer is one plausible reason for reflux. Stomach contents can move back past the muscle that normally keeps them below the food pipe. That explains a possible link; it doesn't prove the cause of every burning throat.
In a four-week human study, tirzepatide slowed stomach emptying after one dose. The effect weakened with repeated doses in healthy participants. Some delay remained during dose increases in participants with type 2 diabetes (Urva and colleagues, Diabetes, Obesity and Metabolism, 2020). The study measured emptying indirectly through absorption of acetaminophen, a pain medicine, rather than testing reflux itself.
What the September 2026 study adds
As of October 1, 2026, the day this article was written, a September 2 study in Gut and Liver adds a reflux signal. Researchers examined side-effect reports from the United States, Japan, and Canada. Their tirzepatide analysis found reflux reported disproportionately in the U.S. and Japanese databases (Choi and colleagues, 2026).
This was an observational reporting study: researchers examined existing reports rather than assigning treatment. It cannot measure how often reflux develops or prove that tirzepatide caused it. Reporting habits and differences between patients can affect the result. The label's trial percentages remain the more useful starting point for the question “how common is it?”
When reflux starts, and how long it lasts
Dose escalation means the step-by-step increases during treatment. Both labels say most nausea, vomiting, and diarrhea occurred during this period and decreased over time. They don't give that same measured timeline for reflux.
So heartburn after a dose increase is a useful detail for the prescriber, but there's no established week when it must disappear. A fading stomach-emptying effect also doesn't guarantee that reflux will fade on the same schedule.
The clinical review considers when symptoms began, whether the dose changed, and whether reflux existed before treatment. The prescriber sets the actual dose and pace. The wider digestive picture is covered in tirzepatide side effects.
Tirzepatide reflux at night
Nighttime burning can make an otherwise manageable symptom feel much worse. Standard reflux care gives clinicians several practical starting points.
The American College of Gastroenterology's 2022 guideline suggests leaving two to three hours between a meal and bedtime. It also suggests raising the head of the bed for nighttime symptoms and reducing foods that personally trigger reflux. These are suggestions with limited supporting evidence, rather than a universal food ban.
The same guideline supports weight loss for people with overweight or obesity and reflux. That doesn't mean tirzepatide treats GERD or that today's burning will resolve with future weight change. Reflux medicines, changes to existing medicines, and any treatment pause are decisions for the clinician reviewing the symptoms.
When symptoms need more than a reflux discussion
The National Institute of Diabetes and Digestive and Kidney Diseases lists chest pain, persistent vomiting, trouble or pain swallowing, and signs of bleeding as reasons for medical assessment. Bleeding may look like blood or coffee grounds in vomit, or black, tarry stools.
Chest pain can also come from the heart. New or severe chest pain warrants urgent assessment, rather than assuming it's heartburn.
Both tirzepatide labels warn about severe digestive reactions and say the brands aren't recommended in severe gastroparesis, a condition where the stomach empties unusually slowly. Severe, persistent belly pain, sometimes spreading to the back, can signal pancreatitis, inflammation of the pancreas, and needs urgent assessment.
Slower emptying also matters during anesthesia or deep sedation, medicines that deeply reduce awareness. Both labels describe rare reports of pulmonary aspiration, when stomach contents enter the lungs, despite reported fasting. The procedure and prescribing teams need the medication history and current symptoms. Semaglutide before surgery explains the shared GLP-1 concern, including tirzepatide, and how teams assess it.
Would switching to semaglutide help?
Semaglutide also acts on GLP-1, a hormone pathway involved in appetite and digestion, and its labels list reflux. The semaglutide acid reflux guide covers that medicine's figures.
A switch may suit an individual, but neither the separate brand trials nor side-effect reporting databases guarantee less heartburn with semaglutide. The choice belongs with the prescriber, weighing the whole treatment history.
What the prescription review covers
Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means a pharmacy prepares a medication for a prescription. The brand-trial percentages don't establish the exact reflux rate for every compounded formulation.
A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and doctor. Existing reflux, trouble swallowing, severe stomach-emptying problems, current medicines, and planned procedures all matter to that review.
At Promise, a licensed provider reviews every request, and not everyone qualifies. Follow-up gives the prescriber a place to assess new heartburn and decide what happens next.
